APRIL 19, 2010

Robert J. Easton Speaks on Evolution of the Pharma Industry

At the Annual Meeting of the New York Biotechnology Association [NYBA] in New York City on April 19, 2010, Robert J. Easton, Chairman of Scisive Consulting, LP organized and moderated a panel entitled Natural Selection in the Pharma Industry: Biotech vs. Big Pharma--Who Eats Whom?  Panelists included Barbara Dalton, VP, Global Business Development of Pfizer Inc., David Ghesquiere, Senior VP, Corporate & Business Development, OSI Pharmaceuticals, Inc., David Gluckman, Managing Director of Lazard, and Joel Papernik, Member of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.

Presentation Abstract: For some years, biotechs have been perceived by many as the likely evolutionary winners in the race for survival and prosperity in the drug industry.  The global financial crisis has drastically altered the environment, perhaps shifting the power back to cash-rich Big Pharma.  So, who will the new winners be, and what strategies must they employ to thrive in these challenging times?

Please request a free copy of Mr. Easton's PowerPoint slides, presentation #NYBA10, at This e-mail address is being protected from spambots. You need JavaScript enabled to view it